This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
The stockprice is at this moment at an all time low, Ive invested in stocks for a while, and I dont think Ive heard such an optimistic leadership like yourself the last years and have nothing to show for it, what do you tell us investors that have worked our hole life to see the money be cut by more than 70% in less than a year after all the delays, missed prognosis, missed agreements, delayed FDA after the agreement first was withdrawn and then coming back? Why should anyone keep there money in your company?
Acoording to the timeline in the Q4 report the FDA approval in China is to be resubmitted in 2024. So you got a rejection without announcing it to the shareholders?
I just wonder why one should keep shares in your company? The shareprice and the lack of providing any form of value to us shareholders is beyond me? After the last report you guys gladly told us shareholders that if you were able to buy on these levels you would, and since then the shareprice have pretty much been cut in half? And we havent seen any insider buys since, the according to MAR news that is shareprice driven should be made public ASAP - and I find it hard to believe that there hasnt been one opportunity to buy the last quarter?
Do you have any recurring customers? And you have said you have agreements in place and just lacking the money to fulfill the orders? How come not every single DDK was used to fulfill those orders?
You have secured a payment from the RongShi JV of 4.9 million. When do you expect to receive that amount?
Can you update on how things are going with the Chinese FDA possible approval?
What happens when the credit line from Danske Bank expires next week?
You transfer IP to the RongShi JV in exchange for the cash payment of 4.9 million. I assume that the JV is going to need a lot of funding in the future. Will you provide 49% of that funding as cash, or do you have further non-cash values that you can contribute to match RongShi's contribution to the JV?
Has the joint venture agreement with RongShi been signed?
In your prospectus for the IPO in 2021, you stated a forecast for 2022/2023 of sales of at least DKK 150 million.
You managed to miss it by 99.3% and come in with 1 MDKK.
How could you be so wrong?
If CS Medica had been a normal listed company (where the management is not the majority owner), the management would have been fired for the long-suffering!